COLGATE PALMOLIVE CO
CLAPI behind this page
CL Q1 2026 request
Playground key active
/api/financials?ticker=CL&year=2026&quarter=1
Pick an endpoint and run the request.Income Statement
| Metric | Q1 2026 | Q1 2025 | YoY |
|---|---|---|---|
| Revenue | 5,324 | 4,911 | +8.4% |
Show Business Segments breakouts |
|||
| Pet Nutrition · Operating Segments | 1,194 | 1,118 | +6.8% |
| Total Oral, Personal and Home Care · Asia Pacific | 804 | 738 | +8.9% |
| Total Oral, Personal and Home Care · EMEA | 1,126 | 1,007 | +11.8% |
| Total Oral, Personal and Home Care · Latin America | 1,313 | 1,143 | +14.9% |
| Total Oral, Personal and Home Care · North America | 888 | 904 | -1.8% |
| Total Oral, Personal and Home Care · Operating Segments | 4,131 | 3,792 | +8.9% |
| Cost of Revenue | 2,098 | 1,924 | +9.0% |
Show Business Segments breakouts |
|||
| Pet Nutrition · Operating Segments | 455 | 437 | +4.1% |
| Total Oral, Personal and Home Care · Asia Pacific | 295 | 275 | +7.3% |
| Total Oral, Personal and Home Care · EMEA | 408 | 367 | +11.2% |
| Total Oral, Personal and Home Care · Latin America | 554 | 487 | +13.8% |
| Total Oral, Personal and Home Care · North America | 390 | 358 | +8.9% |
| Gross Profit | 3,226 | 2,987 | +8.0% |
| Selling, General & Administrative | 2,076 | 1,898 | +9.4% |
Show Business Segments breakouts |
|||
| Pet Nutrition · Operating Segments | 456 | 422 | +8.1% |
| Total Oral, Personal and Home Care · Asia Pacific | 289 | 264 | +9.5% |
| Total Oral, Personal and Home Care · EMEA | 438 | 399 | +9.8% |
| Total Oral, Personal and Home Care · Latin America | 357 | 316 | +13.0% |
| Total Oral, Personal and Home Care · North America | 359 | 350 | +2.6% |
| Other Operating Income Expense Net | 186 | 13 | +1330.8% |
| Operating Income | 964 | 1,076 | -10.4% |
Show Business Segments breakouts |
|||
| Pet Nutrition · Operating Segments | 280 | 258 | +8.5% |
| Total Oral, Personal and Home Care · Asia Pacific | 222 | 204 | +8.8% |
| Total Oral, Personal and Home Care · EMEA | 266 | 222 | +19.8% |
| Total Oral, Personal and Home Care · Latin America | 401 | 348 | +15.2% |
| Total Oral, Personal and Home Care · North America | 141 | 197 | -28.4% |
| Total Oral, Personal and Home Care · Operating Segments | 1,030 | 971 | +6.1% |
Show Consolidation Items breakouts |
|||
| Corporate Non Segment | -346 | -153 | -126.1% |
| Net Periodic Defined Benefits Expense Reversal Of Expense Excluding Service Cost Component | 26 | 72 | -63.9% |
| Interest Expense | 62 | 66 | -6.1% |
| Interest Income | 16 | 15 | +6.7% |
| Income Before Taxes | 892 | 953 | -6.4% |
| Income Tax Expense (Benefit) | 211 | 227 | -7.0% |
| Net Income | 681 | 726 | -6.2% |
Show Equity Components breakouts |
|||
| Noncontrolling Interest | 35 | 36 | -2.8% |
| Retained Earnings | 646 | 690 | -6.4% |
| Net Income Loss Attributable To Noncontrolling Interest | 35 | 36 | -2.8% |
| Net Income | 646 | 690 | -6.4% |
| EPS (Basic) | 0.81 | 0.85 | -4.7% |
| EPS (Diluted) | 0.8 | 0.85 | -5.9% |
| Comprehensive Income | 654 | 795 | -17.7% |
| Wtd Avg Shares (Basic) | 802.3 | 812 | -1.2% |
| Wtd Avg Shares (Diluted) | 805.1 | 815 | -1.2% |
| Net Income Loss Available To Common Stockholders Basic | 646 | 690 | -6.4% |
Balance Sheet
| Metric | Q1 2026 | Q1 2025 | YoY |
|---|---|---|---|
| Current Assets | |||
| Cash & Cash Equivalents | 1,335 | 1,112 | +20.1% |
| Accounts Receivable | 1,889 | 1,725 | +9.5% |
| Inventory | 2,086 | 2,125 | -1.8% |
| Other Assets Current | 772 | 852 | -9.4% |
| Total Current Assets | 6,082 | 5,814 | +4.6% |
| Non-Current Assets | |||
| Property, Plant & Equipment | 4,622 | 4,416 | +4.7% |
| Goodwill | 3,107 | — | — |
Show Business Segments breakouts |
|||
| Asia Pacific Segment · Russia and Belarus | 19 | — | — |
| Deferred Tax Assets | 211 | 211 | 0.0% |
| Other Non-Current Assets | 1,067 | 1,090 | -2.1% |
| Total Assets | 16,610 | 16,647 | -0.2% |
| Other Assets | |||
| Property Plant And Equipment Gross | 10,887 | 10,276 | +5.9% |
| Accumulated Depreciation Depletion And Amortization Property Plant And Equipment | -6,265 | -5,860 | -6.9% |
| Intangible Assets Net Excluding Goodwill | 1,521 | 1,782 | -14.6% |
| Current Liabilities | |||
| Short Term Bank Loans And Notes Payable | 36 | — | — |
| Accounts Payable | 2,096 | 1,800 | +16.4% |
| Accrued Income Taxes Current | 444 | 490 | -9.4% |
| Other Accrued Liabilities Current | 3,358 | 2,873 | +16.9% |
| Total Current Liabilities | 5,934 | 6,861 | -13.5% |
| Non-Current Liabilities | |||
| Long-Term Debt | 7,937 | 6,571 | +20.8% |
| Deferred Tax Liabilities | 198 | 302 | -34.4% |
| Other Non-Current Liabilities | 2,055 | 2,180 | -5.7% |
| Total Liabilities | 16,124 | 15,914 | +1.3% |
| Long-Term Debt (Q) | — | — | — |
Show Fair Value By Measurement Basis breakouts |
|||
| Carrying Reported Amount Fair Value Disclosure | 7,973 | 8,269 | -3.6% |
| Stockholders' Equity | |||
| Common Stock | 1,466 | 1,466 | 0.0% |
| Additional Paid-In Capital | 4,390 | 4,202 | +4.5% |
| Retained Earnings | 26,816 | 26,413 | +1.5% |
| Accumulated Other Comprehensive Income | -3,871 | -4,116 | +6.0% |
| Treasury Stock Common Value | -28,656 | -27,602 | -3.8% |
| Total Stockholders' Equity | 145 | 363 | -60.1% |
| Minority Interest | 341 | 370 | -7.8% |
| Stockholders Equity Including Portion Attributable To Noncontrolling Interest | 486 | 733 | -33.7% |
Show Equity Components breakouts |
|||
| Accumulated Other Comprehensive Income | -3,871 | -4,116 | +6.0% |
| Additional Paid In Capital | 4,390 | 4,202 | +4.5% |
| Common Stock | 1,466 | 1,466 | 0.0% |
| Noncontrolling Interest | 341 | 370 | -7.8% |
| Retained Earnings | 26,816 | 26,413 | +1.5% |
| Treasury Stock Common | -28,656 | -27,602 | -3.8% |
| Total Liabilities & Equity | 16,610 | 16,647 | -0.2% |
Cash Flow Statement
| Metric | YTD Q1 2026 | YTD Q1 2025 | YoY |
|---|---|---|---|
| Operating Activities | |||
| Depreciation & Amortization | 156 | 148 | +5.4% |
Show Business Segments breakouts |
|||
| Pet Nutrition · Operating Segments | 35 | 31 | +12.9% |
| Total Oral, Personal and Home Care · Asia Pacific | 21 | 20 | +5.0% |
| Total Oral, Personal and Home Care · EMEA | 27 | 29 | -6.9% |
| Total Oral, Personal and Home Care · Latin America | 29 | 24 | +20.8% |
| Total Oral, Personal and Home Care · North America | 19 | 19 | 0.0% |
| Total Oral, Personal and Home Care · Operating Segments | 96 | 92 | +4.3% |
Show Consolidation Items breakouts |
|||
| Corporate Non Segment | 25 | 25 | 0.0% |
| Restructuring Net Of Cash | 165 | -7 | +2457.1% |
| Stock-Based Compensation | 40 | 23 | +73.9% |
| Deferred Income Taxes And Tax Credits | -18 | -24 | +25.0% |
| Increase Decrease In Receivables | -215 | -174 | -23.6% |
| Change in Inventory | -41 | -86 | +52.3% |
| Increase Decrease In Accounts Payable And Other Working Capital | -11 | -57 | +80.7% |
| Change in Other Liabilities | -29 | -13 | -123.1% |
| Increase Decrease In Other Noncurrent Assets | 19 | -1 | +2000.0% |
| Net Cash from Operations | 747 | 600 | +24.5% |
| Investing Activities | |||
| Payments To Acquire Productive Assets | -138 | -124 | -11.3% |
| Payments To Acquire Marketable Securities | -70 | -134 | +47.8% |
| Proceeds From Sale And Maturity Of Marketable Securities | 94 | 97 | -3.1% |
| Other Investing Activities | -8 | 2 | -500.0% |
| Net Cash from Investing | -122 | -159 | +23.3% |
| Financing Activities | |||
| Proceeds From Repayments Of Short Term Debt | 1,138 | 164 | +593.9% |
| Repayments Of Other Debt | -1,082 | -4 | -26950.0% |
| Payments Of Ordinary Dividends | -417 | -406 | -2.7% |
| Share Repurchases | -306 | -284 | -7.7% |
| Proceeds From Stock Options Exercised | 127 | 40 | +217.5% |
| Proceeds From Payments For Other Financing Activities | -23 | 32 | -171.9% |
| Net Cash from Financing | -563 | -458 | -22.9% |
| Supplemental | |||
| Income Taxes Paid | 176 | 139 | +26.6% |
| Interest Paid | 96 | 109 | -11.9% |
| Other Cash Flow | |||
| Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | -15 | 33 | -145.5% |
| Net Change in Cash | 47 | 16 | +193.8% |
| Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents | 1,335 | 1,112 | +20.1% |
Values in millions USD. Source: SEC EDGAR 10-Q filing.